MILLENNIUM PHARMACEUTICALS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT00651664
- Locations
- ๐ช๐ธ
H. Clรญnico Universitario de Valencia, Valencia, Spain
๐ช๐ธCiutat Sanitaria Vall d'Hebron - Servicio de Oncologia, Barcelona, Spain
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00636792
- Locations
- ๐บ๐ธ
MidDakota Clinic - Cancer Treatment and Research Center, Bismarck, North Dakota, United States
๐บ๐ธGeorgetown University Medical Center, Washington, District of Columbia, United States
Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT00631631
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
๐บ๐ธU.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00619489
- Locations
- ๐จ๐ฆ
London Health Sciences Centre, London, Ontario, Canada
Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
- Conditions
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT00610792
- Locations
- ๐จ๐ญ
Kantonsspital St. Gallen, St. Gallen, CH, Switzerland
๐จ๐ญGynecologic Oncology Unit, Ospedale Sant' Anna, Turin, Switzerland
๐ฎ๐นIstituto Nazionale dei Tumori, Milan, Italy
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-01-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00608907
- Locations
- ๐ฎ๐ฑ
Hematology Institute - Davidoff Center - Rabin Medical Center, Petach Tikva, Israel
๐ต๐ฑMedical Academy - Dept of Hematology and Transplantology, Gdansk, Poland
๐ฌ๐งHematology Department Combined Laboratories - Derriford Hospital, Plymouth, United Kingdom
Safety Study of TAK-700 in Subjects With Prostate Cancer.
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT00569153
- Locations
- ๐บ๐ธ
USC Westside Prostate Cancer Center, Beverly Hills, California, United States
๐บ๐ธNorthwestern University Medical Center, Chicago, Illinois, United States
๐บ๐ธEvanston Hospital, Evanston, Illinois, United States
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00535522
- Locations
- ๐บ๐ธ
University of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States
๐บ๐ธKarmanos Cancer Center, Detroit, Michigan, United States
๐บ๐ธIndiana University Cancer Center, Indianapolis, Indiana, United States
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT00531453
- Locations
- ๐ฆ๐น
Wilhelminenspital-1, Vienna, Austria
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
- Conditions
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT00507416
- Locations
- ๐บ๐ธ
Hematology Oncology Consultants Inc., Columbus, Ohio, United States
๐บ๐ธS. Florida Oncology/ Hematology, West Palm Beach, Florida, United States
๐บ๐ธHematology-Oncology Clinic, Baton Rouge, Louisiana, United States